ClinicalTrials.gg
CompletedNCT03493542Updated Dec 31, 2024Results posted

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

A Phase 3 interventional study of V501 in Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in China. Open to female participants aged 9 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-31.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
766
Allocation
Non-randomized
Ages
9 Years to 26 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 55 studies in Uterine Cervical Dysplasia with a site in China — 10 open to participants now, 14 under way, 1 of them phase 3. Uterine Cervical Dysplasia · China.

Enrollment
13th of 34
766 · median 330
Started
2018
with 6 others
Phase 3
7 of 55
none open now
Registered
27th of 55
by date

Among the 55 studies in Uterine Cervical Dysplasia with a site in China, this one is the 13th largest by enrollment of the 34 interventional ones that give a count, is one of 7 that started in 2018, is one of 7 in phase 3, and was the 27th registered.

Uterine Cervical Dysplasia

409 studies on the registry are indexed under Uterine Cervical Dysplasia; 76 are open to participants now.

Browse Uterine Cervical Dysplasia studies →

Open to participants now

10 of the 55 studies in Uterine Cervical Dysplasia with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Uterine Cervical Dysplasia studies recruiting now, 19 (44%) set no upper age limit and 21 (49%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.

This study: 9 Years to 26 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Uterine Cervical Dysplasia with a site in China, or all of them as a file.
02

Study summary

This study is designed to evaluate the immunogenicity, safety, and tolerability of Gardasil® (quadrivalent human papillomavirus [qHPV] vaccine, V501) in Chinese girls aged 9-19 years and young women aged 20-26 years. The primary hypothesis of the study states that at 1 month postdose 3, a 3-dose regimen of V501 induces non-inferior geometric mean titers (GMTs) for serum anti-HPV 6, anti-HPV 11, anti-HPV 16, anti-HPV 18 in girls aged 9-19 years compared to young women aged 20-26 years.

Read the detailed description

The study consists of a Base Stage wherein Chinese girls aged 9-19 years and young women aged 20-26 years receive a 3-dose regimen of V501 and are followed up to 1 month postdose 3 (Month 7). Participants aged 9-19 years who received 3 doses of V501 in the Base Stage will be eligible to participate in the Extension Stage and will be followed up to Month 60. No study vaccine will be administered during the Extension Stage.

03

Conditions studied

  • Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
04

Who can participate

Ages eligible
9 Years to 26 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Not pregnant and 1) not a woman of (WOCBP), or 2) a WOCBP who has not had sex with males or has had sex with males and used effective since the first day of participant's last menstrual period through Day 1 and understands and agrees that during the study she should not have sexual intercourse with males without effective contraception (the rhythm method, withdrawal, and emergency contraception are not acceptable methods per the protocol).
  • Participant and participant's parent or guardian (participants aged 9-17 years only) provided written /assent.
  • Provided a primary and alternative telephone for follow-up purposes.
  • Extension Stage: participant was enrolled in the 9-19 years old group, received 3 doses of V501 in the Base Stage, and participant and participant's legally acceptable representative (if applicable) provided written informed consent/assent for the study extension.

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic reaction that required medical intervention.
  • Allergic to any vaccine component, including aluminum, yeast, or Benzonase® (nuclease).
  • Known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
  • Currently or was diagnosed as having congenital or acquired immunodeficiency, (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, or other condition.
  • History of splenectomy.
  • Any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives.
  • History of recent or ongoing alcohol or other drug abuse.
  • History of a positive test for HPV.
  • Any history of abnormal Pap test.
  • History of external genital wart, vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), vulvar cancer or vaginal cancer.
  • Undergone hysterectomy (either vaginal or total abdominal hysterectomy).
  • Receiving or has received in the year prior to Day 1 vaccination an excluded immunosuppressive therapy. A participant will be excluded if she is currently receiving therapy, has recently received such therapy, or has received 2 or more courses of corticosteroids (orally or parenterally) lasting at least 1 week in duration in the year prior to Day 1 vaccination. Participants using inhaled, nasal or topical steroids are considered eligible for the study.
  • Received immune globulin product or blood-derived product within 6 months prior to Day 1 vaccination, or plans to receive any such product during the study.
  • Received a marketed HPV vaccine, or has participated in an HPV vaccine clinical trial and has received either active agent or placebo.
  • Received inactivated or recombinant vaccines within 14 days prior to Day 1 vaccination or receipt of within 21 days prior to Day 1 vaccination.
  • Concurrently enrolled in a clinical study of agents.
  • Had >4 lifetime sexual partners.
  • Unlikely to adhere to the study procedures, keep appointments, or is planning to permanently relocate from the area prior to the completion of the study or to leave for an extended period of time when study visits would need to be scheduled.
  • An immediate family member who is investigational site or sponsor staff directly involved with this study.
  • Extension Stage: reported overdose or received non-study HPV vaccine during the Base Stage.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
766 participants (actual)

Study arms

  • Experimental
    Chinese Girls Aged 9 to 19 Years

    Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6

    Biological: V501

  • Active comparator
    Chinese Young Women Aged 20 to 26 Years

    Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6

    Biological: V501

Interventions

  • BiologicalV501

    0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6

    Also known as: (Gardasil®) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, qHPV

06

What researchers measure

Primary outcomes

  1. Base Stage: Geometric Mean Titers for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18: Competitive Luminex Immunoassay (cLIA)

    Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as milli Merck Units/milliliter (mMU/mL).

    Time frame: Month 7 (1 month postdose 3)

  2. Extension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 12 Assessed by cLIA

    Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).

    Time frame: Month 12 post-vaccination 1

  3. Extension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 24 Assessed by cLIA

    Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).

    Time frame: Month 24 post-vaccination 1

  4. Extension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 36 Assessed by cLIA

    Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).

    Time frame: Month 36 post-vaccination 1

  5. Extension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 48 Assessed by cLIA

    Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).

    Time frame: Month 48 post-vaccination 1

  6. Extension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 60 Assessed by cLIA

    Serum antibody titers (Geometric mean titers) for HPV virus-like particles (VLPs) Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).

    Time frame: Month 60 post-vaccination 1

  7. Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 12 Assessed by cLIA

    The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.

    Time frame: Month 12 post-vaccination 1

  8. Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 24 Assessed by cLIA

    The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.

    Time frame: Month 24 post-vaccination 1

  9. Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 36 Assessed by cLIA

    The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.

    Time frame: Month 36 post-vaccination 1

  10. Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 48 Assessed by cLIA

    The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.

    Time frame: Month 48 post-vaccination 1

  11. Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 60 Assessed by cLIA

    The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.

    Time frame: Month 60 post-vaccination 1

  12. Extension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 12 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)

    Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA. Antibody titers were expressed as (mMU/mL).

    Time frame: Month 12 post-vaccination 1

  13. Extension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 24 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)

    Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA. Antibody titers were expressed as (mMU/mL).

    Time frame: Month 24 post-vaccination 1

  14. Extension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 36 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)

    Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA. Antibody titers were expressed as (mMU/mL).

    Time frame: Month 36 post-vaccination 1

  15. Extension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 48 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)

    Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA.

    Time frame: Month 48 post-vaccination 1

  16. Extension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 60 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)

    Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA.

    Time frame: Month 60 post-vaccination 1

  17. Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 12 Assessed by IgG LIA

    The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.

    Time frame: Month 12 post-vaccination 1

  18. Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 24 Assessed by IgG LIA

    The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.

    Time frame: Month 24 post-vaccination 1

  19. Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 36 Assessed by IgG LIA

    The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.

    Time frame: Month 36 post-vaccination 1

  20. Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 48 Assessed by IgG LIA

    The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.

    Time frame: Month 48 post-vaccination 1

  21. Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 60 Assessed by IgG LIA

    The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.

    Time frame: Month 60 post-vaccination 1

Secondary outcomes

  1. Base Stage: Percentage of Participants With Seroconversion for HPV Types 6, 11, 16, and 18: cLIA

    Seroconversion is defined as changing serostatus from seronegative at Day 1 to seropositive at 1 month post dose 3. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as milli Merck Units/milliliter (mMU/mL).

    Time frame: Month 7 (1 month postdose 3)

  2. Base Stage: Geometric Mean Titers for Serum Anti-HPV Types 6, 11, 16, and 18: IgG LIA

    Antibodies to HPV Types 6, 11, 16, and 18 were measured using an IgG LIA. Antibody titers were expressed as milli Merck Units/milliliter (mMU/mL).

    Time frame: Month 7 (1 month postdose 3)

  3. Base Stage: Percentage of Participants With Seroconversion for HPV Types 6, 11, 16, and 18: IgG LIA

    The percentage of participants who seroconverted to each of HPV Types 6, 11, 16, and 18 was assessed. Antibodies were measured using IgG LIA.

    Time frame: Month 7 (1 month postdose 3)

  4. Base Stage: Percentage of Participants Who Experienced a Solicited Injection-site Adverse Event (AE)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs included injection-site redness, swelling, induration, pain, and pruritus.

    Time frame: Up to 15 days after any vaccination

  5. Base Stage: Percentage of Participants Participants Who Experienced a Solicited Systemic AE

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs included hypersensitivity, headache, fatigue, vomiting, nausea, diarrhea, myalgia, pyrexia, and cough.

    Time frame: Up to 15 days after any vaccination

  6. Base Stage: Percentage of Participants Who Experienced a Serious Adverse Event (SAE)

    An SAE is an AE that results in death, is life threatening, requires hospitalization or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, according to medical or scientific judgment, may jeopardize the participant or requires medical or surgical intervention to prevent one of the other outcomes listed in the above definition.

    Time frame: Up to Month 7 (1 month postdose 3)

  7. Base Stage: Percentage of Participants Who Experienced an AE

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment

    Time frame: Up to 31 days after any vaccination

  8. Base Stage: Maximum Axillary Temperature: Merck Sharp & Dohme (MSD) Criteria

    In the global studies, fever is defined as an oral temperature of ≥37.8°C or 100.0°F, which is equivalent to axillary temperature of ≥37.2°C, while the definition of fever is axillary temperature of ≥37.1°C in Chinese criteria. To be compliant to Chinese criteria, axillary temperatures of ≥37.1°C was considered as a fever in this study. Body temperature readings assessed orally were converted to the axillary equivalent. The percentage of participants with a maximum axillary or converted axillary temperature was summarized by temperature range.

    Time frame: Up to 5 days after any vaccination

  9. Extension Stage: Percentage of Participants Who Experienced an SAE

    The percentage of participants with an SAE will be assessed. An SAE is an AE that results in death, is life threatening, requires hospitalization or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, according to medical or scientific judgment, may jeopardize the participant or requires medical or surgical intervention to prevent one of the other outcomes listed in the above definition.

    Time frame: Month 7 up to Month 60

07

Results

Posted May 4, 2020

Participant flow

Base Study
Participant flow — Base Study
MilestoneBase Study: Chinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 YearsExtension Study: Chinese Girls Aged 9 to 19 Years
Started3833830
Vaccination 13833830
Vaccination 23793780
Vaccination 33783770
Completed3833790
Not completed040
Withdrew: Withdrawal by subject040
Extension Study
Participant flow — Extension Study
MilestoneBase Study: Chinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 YearsExtension Study: Chinese Girls Aged 9 to 19 Years
Started00365
Completed00338
Not completed0027
Withdrew: Consent withdrawal by parent/guardian002
Withdrew: Withdrawal by subject0025

Outcome measures

PrimaryBase Stage: Geometric Mean Titers for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18: Competitive Luminex Immunoassay (cLIA)

Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as milli Merck Units/milliliter (mMU/mL).

Time frame:
Month 7 (1 month postdose 3)
Reported as:
Geometric mean · mMU/mL
Base Stage: Geometric Mean Titers for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18: Competitive Luminex Immunoassay (cLIA)
mMU/mLChinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 Years
Anti-HPV 6975.2 (905.6 to 1050.2)686.6 (635.5 to 741.7)
Anti-HPV 11807.4 (749.8 to 869.4)580.2 (537.0 to 626.8)
Anti-HPV 164573.7 (4244.5 to 4928.3)2989.2 (2766.7 to 3229.6)
Anti-HPV 181176.5 (1069.0 to 1294.8)708.6 (642.4 to 781.6)
Statistical analysis
  • Chinese Girls Aged 9 to 19 Years vs Base Study: Chinese Young Women Aged 20 to 26 Years · ANOVA · p = <0.0001 · Gmt ratio: 1.42 · 95% CI 1.28 to 1.58GMT Ratio = GMT (9-19 yr)/GMT(20-26 yr)
  • Chinese Girls Aged 9 to 19 Years vs Base Study: Chinese Young Women Aged 20 to 26 Years · ANOVA · p = <0.0001 · Gmt ratio: 1.39 · 95% CI 1.25 to 1.55GMT Ratio = GMT (9-19 yr)/GMT(20-26 yr)
  • Chinese Girls Aged 9 to 19 Years vs Base Study: Chinese Young Women Aged 20 to 26 Years · ANOVA · p = <0.0001 · Gmt ratio: 1.53 · 95% CI 1.37 to 1.70GMT Ratio = GMT (9-19 yr)/GMT(20-26 yr)
  • Chinese Girls Aged 9 to 19 Years vs Base Study: Chinese Young Women Aged 20 to 26 Years · ANOVA · p = <0.0001 · Gmt ratio: 1.66 · 95% CI 1.45 to 1.90GMT Ratio = GMT (9-19 yr)/GMT(20-26 yr)
PrimaryExtension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 12 Assessed by cLIA

Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).

Time frame:
Month 12 post-vaccination 1
Reported as:
Geometric mean · mMU/mL
Extension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 12 Assessed by cLIA
mMU/mLExtension Study: Chinese Girls Aged 9 to 19 Years
Anti-HPV 6259.1 (237.6 to 282.4)
Anti-HPV 11206.7 (190.5 to 224.3)
Anti-HPV 161149.8 (1054.6 to 1253.7)
Anti-HPV 18284.2 (257.3 to 313.8)
PrimaryExtension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 24 Assessed by cLIA

Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).

Time frame:
Month 24 post-vaccination 1
Reported as:
Geometric mean · mMU/mL
Extension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 24 Assessed by cLIA
mMU/mLExtension Study: Chinese Girls Aged 9 to 19 Years
Anti-HPV 6137.9 (125.5 to 151.4)
Anti-HPV 11110.3 (101.0 to 120.6)
Anti-HPV 16522.6 (472.1 to 578.5)
Anti-HPV 18157.2 (142.7 to 173.3)
PrimaryExtension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 36 Assessed by cLIA

Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).

Time frame:
Month 36 post-vaccination 1
Reported as:
Geometric mean · mMU/mL
Extension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 36 Assessed by cLIA
mMU/mLExtension Study: Chinese Girls Aged 9 to 19 Years
Anti-HPV 6110.6 (101.3 to 120.7)
Anti-HPV 1187.0 (79.6 to 95.2)
Anti-HPV 16400.8 (359.5 to 446.8)
Anti-HPV 18131.9 (120.2 to 144.8)
PrimaryExtension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 48 Assessed by cLIA

Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).

Time frame:
Month 48 post-vaccination 1
Reported as:
Geometric mean · mMU/mL
Extension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 48 Assessed by cLIA
mMU/mLExtension Study: Chinese Girls Aged 9 to 19 Years
Anti-HPV 6103.0 (94.4 to 112.4)
Anti-HPV 1181.8 (74.8 to 89.3)
Anti-HPV 16347.5 (310.0 to 389.6)
Anti-HPV 18130.3 (118.9 to 142.7)
PrimaryExtension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 60 Assessed by cLIA

Serum antibody titers (Geometric mean titers) for HPV virus-like particles (VLPs) Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).

Time frame:
Month 60 post-vaccination 1
Reported as:
Geometric mean · mMU/mL
Extension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 60 Assessed by cLIA
mMU/mLExtension Study: Chinese Girls Aged 9 to 19 Years
Anti-HPV 687.6 (80.4 to 95.4)
Anti-HPV 1167.3 (61.6 to 73.5)
Anti-HPV 16283.2 (250.8 to 319.8)
Anti-HPV 18113.6 (103.7 to 124.5)
PrimaryExtension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 12 Assessed by cLIA

The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.

Time frame:
Month 12 post-vaccination 1
Reported as:
Number · Percentage of Participants
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 12 Assessed by cLIA
Percentage of ParticipantsExtension Study: Chinese Girls Aged 9 to 19 Year
Anti-HPV 699.1 (97.4 to 99.8)
Anti-HPV 1199.7 (98.3 to 100.0)
Anti-HPV 16100.0 (98.9 to 100.0)
Anti-HPV 1896.9 (94.3 to 98.5)
PrimaryExtension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 24 Assessed by cLIA

The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.

Time frame:
Month 24 post-vaccination 1
Reported as:
Number · Percentage of Participants
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 24 Assessed by cLIA
Percentage of ParticipantsExtension Study: Chinese Girls Aged 9 to 19 Year
Anti-HPV 688.8 (84.9 to 92.0)
Anti-HPV 1195.3 (92.4 to 97.4)
Anti-HPV 1699.7 (98.3 to 100.0)
Anti-HPV 1887.7 (83.5 to 91.1)
PrimaryExtension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 36 Assessed by cLIA

The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.

Time frame:
Month 36 post-vaccination 1
Reported as:
Number · Percentage of Participants
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 36 Assessed by cLIA
Percentage of ParticipantsExtension Study: Chinese Girls Aged 9 to 19 Year
Anti-HPV 683.6 (79.1 to 87.5)
Anti-HPV 1192.1 (88.6 to 94.8)
Anti-HPV 1698.8 (96.9 to 99.7)
Anti-HPV 1884.0 (79.4 to 87.9)
PrimaryExtension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 48 Assessed by cLIA

The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.

Time frame:
Month 48 post-vaccination 1
Reported as:
Number · Percentage of Participants
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 48 Assessed by cLIA
Percentage of ParticipantsExtension Study: Chinese Girls Aged 9 to 19 Year
Anti-HPV 668.5 (63.0 to 73.6)
Anti-HPV 1185.2 (80.8 to 89.0)
Anti-HPV 1691.9 (88.4 to 94.6)
Anti-HPV 1864.6 (58.9 to 70.0)
PrimaryExtension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 60 Assessed by cLIA

The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.

Time frame:
Month 60 post-vaccination 1
Reported as:
Number · Percentage of Participants
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 60 Assessed by cLIA
Percentage of ParticipantsExtension Study: Chinese Girls Aged 9 to 19 Year
Anti-HPV 661.9 (56.2 to 67.3)
Anti-HPV 1174.9 (69.7 to 79.7)
Anti-HPV 1687.1 (82.9 to 90.6)
Anti-HPV 1858.3 (52.5 to 63.9)
PrimaryExtension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 12 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)

Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA. Antibody titers were expressed as (mMU/mL).

Time frame:
Month 12 post-vaccination 1
Reported as:
Geometric mean · mMU/mL
Extension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 12 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)
mMU/mLExtension Study: Chinese Girls Aged 9 to 19 Years
Anti-HPV 6217.0 (198.1 to 237.6)
Anti-HPV 11172.1 (158.3 to 187.1)
Anti-HPV 161025.8 (945.5 to 1113.0)
Anti-HPV 18228.0 (204.4 to 254.4)
PrimaryExtension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 24 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)

Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA. Antibody titers were expressed as (mMU/mL).

Time frame:
Month 24 post-vaccination 1
Reported as:
Geometric mean · mMU/mL
Extension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 24 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)
mMU/mLExtension Study: Chinese Girls Aged 9 to 19 Years
Anti-HPV 685.5 (76.4 to 95.6)
Anti-HPV 1168.6 (61.6 to 76.4)
Anti-HPV 16394.9 (354.6 to 439.9)
Anti-HPV 1876.9 (67.0 to 88.3)
PrimaryExtension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 36 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)

Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA. Antibody titers were expressed as (mMU/mL).

Time frame:
Month 36 post-vaccination 1
Reported as:
Geometric mean · mMU/mL
Extension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 36 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)
mMU/mLExtension Study: Chinese Girls Aged 9 to 19 Years
Anti-HPV 666.5 (59.6 to 74.1)
Anti-HPV 1152.7 (47.2 to 58.8)
Anti-HPV 16304.0 (272.2 to 339.5)
Anti-HPV 1857.5 (50.0 to 66.1)
PrimaryExtension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 48 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)

Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA.

Time frame:
Month 48 post-vaccination 1
Reported as:
Geometric mean · mMU/mL
Extension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 48 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)
mMU/mLExtension Study: Chinese Girls Aged 9 to 19 Year
Anti-HPV 663.4 (56.8 to 70.8)
Anti-HPV 1151.1 (45.9 to 56.9)
Anti-HPV 16289.6 (258.7 to 324.2)
Anti-HPV 1855.3 (47.8 to 63.9)
PrimaryExtension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 60 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)

Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA.

Time frame:
Month 60 post-vaccination 1
Reported as:
Geometric mean · mMU/mL
Extension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 60 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)
mMU/mLExtension Study: Chinese Girls Aged 9 to 19 Year
Anti-HPV 658.6 (52.5 to 65.4)
Anti-HPV 1147.2 (42.4 to 52.5)
Anti-HPV 16264.3 (235.8 to 296.3)
Anti-HPV 1851.0 (44.0 to 59.1)
PrimaryExtension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 12 Assessed by IgG LIA

The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.

Time frame:
Month 12 post-vaccination 1
Reported as:
Number · Percentage of Participants
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 12 Assessed by IgG LIA
Percentage of ParticipantsExtension Study: Chinese Girls Aged 9 to 19 Year
Anti-HPV 6100.0 (98.9 to 100.0)
Anti-HPV 11100.0 (98.9 to 100.0)
Anti-HPV 16100.0 (98.9 to 100.0)
Anti-HPV 18100.0 (98.9 to 100.0)
PrimaryExtension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 24 Assessed by IgG LIA

The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.

Time frame:
Month 24 post-vaccination 1
Reported as:
Number · Percentage of Participants
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 24 Assessed by IgG LIA
Percentage of ParticipantsExtension Study: Chinese Girls Aged 9 to 19 Year
Anti-HPV 698.4 (96.4 to 99.5)
Anti-HPV 1198.4 (96.4 to 99.5)
Anti-HPV 16100.0 (98.9 to 100.0)
Anti-HPV 1898.1 (95.9 to 99.3)
PrimaryExtension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 36 Assessed by IgG LIA

The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.

Time frame:
Month 36 post-vaccination 1
Reported as:
Number · Percentage of Participants
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 36 Assessed by IgG LIA
Percentage of ParticipantsExtension Study: Chinese Girls Aged 9 to 19 Year
Anti-HPV 698.1 (95.9 to 99.3)
Anti-HPV 1199.4 (97.7 to 99.9)
Anti-HPV 16100.0 (98.9 to 100.0)
Anti-HPV 1896.2 (93.4 to 98.0)
PrimaryExtension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 48 Assessed by IgG LIA

The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.

Time frame:
Month 48 post-vaccination 1
Reported as:
Geometric mean · Percentage of Participants
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 48 Assessed by IgG LIA
Percentage of ParticipantsExtension Study: Chinese Girls Aged 9 to 19 Year
Anti-HPV 697.4 (95.0 to 98.9)
Anti-HPV 1198.4 (96.3 to 99.5)
Anti-HPV 16100.0 (98.9 to 100.0)
Anti-HPV 1895.1 (92.0 to 97.2)
PrimaryExtension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 60 Assessed by IgG LIA

The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.

Time frame:
Month 60 post-vaccination 1
Reported as:
Number · Percentage of Participants
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 60 Assessed by IgG LIA
Percentage of ParticipantsExtension Study: Chinese Girls Aged 9 to 19 Year
Anti-HPV 696.7 (94.1 to 98.4)
Anti-HPV 1198.4 (96.2 to 99.5)
Anti-HPV 16100.0 (98.8 to 100.0)
Anti-HPV 1895.4 (92.3 to 97.4)
SecondaryBase Stage: Percentage of Participants With Seroconversion for HPV Types 6, 11, 16, and 18: cLIA

Seroconversion is defined as changing serostatus from seronegative at Day 1 to seropositive at 1 month post dose 3. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as milli Merck Units/milliliter (mMU/mL).

Time frame:
Month 7 (1 month postdose 3)
Reported as:
Number · Percentage of Participants
Base Stage: Percentage of Participants With Seroconversion for HPV Types 6, 11, 16, and 18: cLIA
Percentage of ParticipantsBase Study: Chinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 Years
Anti-HPV 6100.0100.0
Anti-HPV 11100.0100.0
Anti-HPV 16100.0100.0
Anti-HPV 18100.0100.0
Statistical analysis
  • Base Study: Chinese Girls Aged 9 to 19 Years vs Base Study: Chinese Young Women Aged 20 to 26 Years · Miettinen & Nurminen method · p = <0.0001 · Difference in percentages (%): 0.0 · 95% CI -1.1 to 1.2
  • Base Study: Chinese Girls Aged 9 to 19 Years vs Base Study: Chinese Young Women Aged 20 to 26 Years · Miettinen & Nurminen method · p = <0.0001 · Difference in percentages (%): 0.0 · 95% CI -1.1 to 1.2
  • Base Study: Chinese Girls Aged 9 to 19 Years vs Base Study: Chinese Young Women Aged 20 to 26 Years · Miettinen & Nurminen method · p = <0.0001 · Difference in percentages (%): 0.0 · 95% CI -1.1 to 1.2
  • Base Study: Chinese Girls Aged 9 to 19 Years vs Base Study: Chinese Young Women Aged 20 to 26 Years · Miettinen & Nurminen method · p = <0.0001 · Difference in percentages (%): 0.0 · 95% CI -1.1 to 1.2
SecondaryBase Stage: Geometric Mean Titers for Serum Anti-HPV Types 6, 11, 16, and 18: IgG LIA

Antibodies to HPV Types 6, 11, 16, and 18 were measured using an IgG LIA. Antibody titers were expressed as milli Merck Units/milliliter (mMU/mL).

Time frame:
Month 7 (1 month postdose 3)
Reported as:
Geometric mean · mMU/mL
Base Stage: Geometric Mean Titers for Serum Anti-HPV Types 6, 11, 16, and 18: IgG LIA
mMU/mLBase Study: Chinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 Years
Anti-HPV 6902.7 (831.2 to 980.3)604.5 (554.7 to 658.8)
Anti-HPV 11756.2 (695.7 to 821.9)518.7 (475.5 to 565.9)
Anti-HPV 164170.0 (3849.3 to 4517.4)2659.3 (2447.8 to 2889.0)
Anti-HPV 181012.8 (918.7 to 1116.5)612.0 (553.9 to 676.1)
SecondaryBase Stage: Percentage of Participants With Seroconversion for HPV Types 6, 11, 16, and 18: IgG LIA

The percentage of participants who seroconverted to each of HPV Types 6, 11, 16, and 18 was assessed. Antibodies were measured using IgG LIA.

Time frame:
Month 7 (1 month postdose 3)
Reported as:
Number · Percentage of Participants
Base Stage: Percentage of Participants With Seroconversion for HPV Types 6, 11, 16, and 18: IgG LIA
Percentage of ParticipantsBase Study: Chinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 Years
Anti-HPV 6100.0100.0
Anti-HPV 11100.0100.0
Anti-HPV 16100.0100.0
Anti-HPV 18100.0100.0
SecondaryBase Stage: Percentage of Participants Who Experienced a Solicited Injection-site Adverse Event (AE)

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs included injection-site redness, swelling, induration, pain, and pruritus.

Time frame:
Up to 15 days after any vaccination
Reported as:
Number · Percentage of Participants
Base Stage: Percentage of Participants Who Experienced a Solicited Injection-site Adverse Event (AE)
Percentage of ParticipantsBase Study: Chinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 Years
Base Stage: Percentage of Participants Who Experienced a Solicited Injection-site Adverse Event (AE)36.640.7
SecondaryBase Stage: Percentage of Participants Participants Who Experienced a Solicited Systemic AE

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs included hypersensitivity, headache, fatigue, vomiting, nausea, diarrhea, myalgia, pyrexia, and cough.

Time frame:
Up to 15 days after any vaccination
Reported as:
Number · Percentage of Participants
Base Stage: Percentage of Participants Participants Who Experienced a Solicited Systemic AE
Percentage of ParticipantsChinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 Years
Base Stage: Percentage of Participants Participants Who Experienced a Solicited Systemic AE39.942.0
SecondaryBase Stage: Percentage of Participants Who Experienced a Serious Adverse Event (SAE)

An SAE is an AE that results in death, is life threatening, requires hospitalization or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, according to medical or scientific judgment, may jeopardize the participant or requires medical or surgical intervention to prevent one of the other outcomes listed in the above definition.

Time frame:
Up to Month 7 (1 month postdose 3)
Reported as:
Number · Percentage of Participants
Base Stage: Percentage of Participants Who Experienced a Serious Adverse Event (SAE)
Percentage of ParticipantsChinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 Years
Base Stage: Percentage of Participants Who Experienced a Serious Adverse Event (SAE)1.62.87
SecondaryBase Stage: Percentage of Participants Who Experienced an AE

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment

Time frame:
Up to 31 days after any vaccination
Reported as:
Number · Percentage of Participants
Base Stage: Percentage of Participants Who Experienced an AE
Percentage of ParticipantsChinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 Years
Base Stage: Percentage of Participants Who Experienced an AE61.668.9
SecondaryBase Stage: Maximum Axillary Temperature: Merck Sharp & Dohme (MSD) Criteria

In the global studies, fever is defined as an oral temperature of ≥37.8°C or 100.0°F, which is equivalent to axillary temperature of ≥37.2°C, while the definition of fever is axillary temperature of ≥37.1°C in Chinese criteria. To be compliant to Chinese criteria, axillary temperatures of ≥37.1°C was considered as a fever in this study. Body temperature readings assessed orally were converted to the axillary equivalent. The percentage of participants with a maximum axillary or converted axillary temperature was summarized by temperature range.

Time frame:
Up to 5 days after any vaccination
Reported as:
Number · Percentage of Participants
Base Stage: Maximum Axillary Temperature: Merck Sharp & Dohme (MSD) Criteria
Percentage of ParticipantsChinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 Years
< 37.2 °C (99.0 °F)87.284.9
≥37.2 °C (99.0 °F) and < 38.3 °C (100.9 °F)12.314.9
≥ 38.3 °C (100.9 °F) and < 39.3 °C (102.7 °F)0.30.3
≥ 39.3 °C (102.7 °F) and < 40.3 °C (104.5 °F)0.30.0
≥ 40.3 °C (104.5 °F)0.00.0
SecondaryExtension Stage: Percentage of Participants Who Experienced an SAE

The percentage of participants with an SAE will be assessed. An SAE is an AE that results in death, is life threatening, requires hospitalization or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, according to medical or scientific judgment, may jeopardize the participant or requires medical or surgical intervention to prevent one of the other outcomes listed in the above definition.

Time frame:
Month 7 up to Month 60
Reported as:
Number · Percentage of Participants
Extension Stage: Percentage of Participants Who Experienced an SAE
Percentage of ParticipantsExtension Study: Chinese Girls Aged 9 to 19 Years
Extension Stage: Percentage of Participants Who Experienced an SAE2.2

Adverse events

Collected over Base Stage only: Up to approximately 7 months Extension Stage: Month 7 up to approximately 60 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Base Study: Chinese Girls Aged 9 to 19 Years0/383 (0%)6/383 (1.6%)216/383 (56.4%)
Base Study: Chinese Young Women Aged 20 to 26 Years0/383 (0%)11/383 (2.9%)238/383 (62.1%)
Extension Study: Chinese Girls Aged 9 to 19 Years0/365 (0%)8/365 (2.2%)0/365 (0%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventBase Study: Chinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 YearsExtension Study: Chinese Girls Aged 9 to 19 Years
Hyperemesis gravidarumPregnancy, puerperium and perinatal conditions0/3830/3832/365
Skin infectionInfections and infestations0/3830/3831/365
Ligament sprainInjury, poisoning and procedural complications0/3830/3831/365
Post procedural haemorrhageInjury, poisoning and procedural complications0/3830/3831/365
Ulna fractureInjury, poisoning and procedural complications0/3830/3831/365
EpendymomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3830/3831/365
Abortion threatenedPregnancy, puerperium and perinatal conditions0/3830/3831/365
Ectopic pregnancyPregnancy, puerperium and perinatal conditions0/3830/3831/365
Foetal distress syndromePregnancy, puerperium and perinatal conditions0/3830/3831/365
DermatitisSkin and subcutaneous tissue disorders0/3830/3831/365
Most frequent other events
Most frequent other events
EventBase Study: Chinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 YearsExtension Study: Chinese Girls Aged 9 to 19 Years
Injection site painGeneral disorders122/383152/3830/365
PyrexiaGeneral disorders104/383108/3830/365
FatigueGeneral disorders41/38342/3830/365
HeadacheNervous system disorders32/38342/3830/365
CoughRespiratory, thoracic and mediastinal disorders37/38341/3830/365
Injection site pruritusGeneral disorders32/38316/3830/365
DiarrhoeaGastrointestinal disorders15/38331/3830/365
Oropharyngeal painRespiratory, thoracic and mediastinal disorders16/38329/3830/365
Injection site swellingGeneral disorders22/38311/3830/365

Baseline characteristics

Per protocol, baseline characteristics were analyzed in all participants randomized in the base study.

Age, Continuous
Age, Continuous(years)Base Study: Chinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 YearsTotal
Mean14.3 ± 3.323.4 ± 1.818.8 ± 5.3
Sex: Female, Male
Sex: Female, Male(Participants)Base Study: Chinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 YearsTotal
Female383383766
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Base Study: Chinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 YearsTotal
Hispanic or Latino000
Not Hispanic or Latino383383766
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Base Study: Chinese Girls Aged 9 to 19 YearsBase Study: Chinese Young Women Aged 20 to 26 YearsTotal
American Indian or Alaska Native000
Asian383383766
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Yangchun Center For Disease Prevention And Control ( Site 0003)
    Yangchun, Guangdong 529600, China
09

References and documents

Publications

  • Huang Z, He J, Su J, Ou Z, Liu G, Fu R, Shou Q, Zheng M, Group T, Luxembourg A, Liao X, Zhang J. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study. Vaccine. 2021 Jan 22;39(4):760-766. doi: 10.1016/j.vaccine.2020.11.008. Epub 2020 Nov 22. PubMed 33239228 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Oct 2023, 61 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2018
First posted
Apr 10, 2018
StartActual
Aug 31, 2018
Primary completionActual
Oct 30, 2023
CompletionActual
Oct 30, 2023
Results first posted
May 4, 2020
Last update
Dec 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03493542
Responsible party
Sponsor
First posted
Apr 10, 2018
Start date
Aug 31, 2018
Primary completion
Oct 30, 2023
Completion
Oct 30, 2023
Results posted
May 4, 2020
Last update
Dec 31, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18

Start the discussion